Public Release: 

Study shows acetaminophen can be tolerated by young children with mild, persistent asthma

NIH/National Heart, Lung and Blood Institute

WIn a study of children with mild, persistent asthma, scientists found that acetaminophen was tolerated without the worsening of asthma, when compared with ibuprofen use. The study, funded by the National Heart, Lung, and Blood Institute's asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.

While acetaminophen (e.g., Tylenol, Panadol) and ibuprofen (e.g., Advil, Motrin) are often used to treat pain or fevers in children, some prior reports suggested that use of acetaminophen in children with asthma was associated with the worsening of asthma. Consequently, some health care providers avoided the use of acetaminophen in children with the disease.

To assess the impact of acetaminophen use on children's asthma, AsthmaNet investigators studied 300 children, aged 1 to 5 years old, who had mild, persistent asthma, defined as symptoms on more than 2 days out of a week but not daily. All children required daily inhaled treatments to manage their asthma. During the study, caregivers used either acetaminophen or ibuprofen whenever a child needed pain relief or had a fever. None of the study investigators, children, or caregivers knew which study drug each child was receiving.

The scientists did not detect any worsening of asthma in the children treated with acetaminophen compared with those receiving ibuprofen. This was measured by asthma exacerbation rate, the number of days of asthma control, the need for rescue medications, and unscheduled medical visits for asthma. They also did not find any significant differences in safety between the two drugs.

While the authors noted that these results should be used to treat pain or fevers in children with characteristics similar to those studied, the results could impact the care of many children with asthma.


WHO: Michelle Freemer, MD, a Program Director in the Division of Lung Diseases and Sleep at the National Heart, Lung, and Blood Institute, is available to comment on the findings and implications of this research.

CONTACT: For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or (link sends e-mail).

About NHLBI: Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans,conducts, and supports research related to the causes, prevention, diagnosis,and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at

About the National Institutes of Health (NIH): NIH, the nation's medical research agency,includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIH... Turning Discovery Into Health

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.